

**GOVERNMENT OF INDIA  
MINISTRY OF CHEMICALS AND FERTILIZERS  
DEPARTMENT OF PHARMACEUTICALS**

LOK SABHA  
STARRED QUESTION NO. †\*419  
TO BE ANSWERED ON THE 20<sup>TH</sup> MARCH, 2026

**Biopharma Shakti Scheme**

†\*419. **Shri Bidyut Baran Mahato:**  
**Smt. Aparajita Sarangi:**

Will the Minister of **CHEMICALS AND FERTILIZERS** be pleased to state:

- (a) the details of allocation and the proposed distribution of funds under the Biopharma Shakti Scheme over the next five years, year-wise;
- (b) the steps taken/proposed to be taken for establishment of recognized clinical trial sites in the country including Chhattisgarh and the expected outcomes thereof;
- (c) the steps taken to strengthen the regulatory framework, including capacity building of the Central Drugs Standard Control Organization (CDSCO) for expeditious approval of biologics and biosimilars; and
- (d) the process likely to be followed to reduce import dependency and increase India's share in the global biopharmaceutical market through the said scheme?

**ANSWER**

**THE MINISTER IN THE MINISTRY OF CHEMICALS AND FERTILIZERS  
(SHRI JAGAT PRAKASH NADDA)**

---

(a) to (d): A statement is laid on the Table of the House

**Statement referred to in reply to the Lok Sabha Starred Question No. †\*419 (19<sup>th</sup> Position) for answer on 20.03.2026, raised by Shri Bidyut Baran Mahato and Smt. Aparajita Sarangi, regarding “Biopharma Shakti Scheme”**

With a view to strengthen the domestic biopharmaceutical sector and enhance global competitiveness in biologics and biosimilars, the Government has announced the Biopharma SHAKTI scheme with an outlay of ₹10,000 crore over five years with an objective to build a globally competitive domestic ecosystem for biologics and biosimilars to support affordable healthcare in India and enable India to emerge as a global biopharma manufacturing and innovation hub. The contours of the scheme are under deliberation.

Under the scheme, it is envisaged to enable faster, globally credible approvals by strengthening the CDSCO through creation of a dedicated Scientific Review Cadre of reviewers and specialist positions for advanced fields like gene therapy. It is also envisaged to expand India’s clinical research footprint by creating a nationally accredited network of 1,000 clinical trial sites under ICMR.

The Biopharma SHAKTI initiative envisages to build the ecosystem for domestic production of biologics and bio-similars. Further by supporting research and development, strengthening clinical trial infrastructure and promoting collaboration between academia, research institutions and industry, the Scheme seeks to encourage domestic innovation and manufacturing capabilities in the biopharmaceutical sector. Such initiatives are expected to contribute towards reducing import dependence over time and enhance India’s participation in the global biopharmaceutical market.

\*\*\*\*\*